Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A disease involving a pathogenic inflammatory response in the anatomical structure.
Clinical Trials37 registered · 15 recruiting
Diagnosis
Biomarker and diagnostic research for inflammatory disease has been reported in the published literature.
Research Landscape
Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.
37 clinical trials registered, 15 recruiting. Interventions under study include other interventions, drug therapy, procedural interventions, and medical devices. Pipeline includes 2 PHASE4, 1 PHASE3, 2 PHASE2. Research is sponsored by a mix of industry and academic institutions.
Diseases are connected by shared genes, phenotypes, therapeutic targets, and MONDO disease hierarchy. The Rare badge reflects Kisho's rarity classification — scored from authoritative sources including OMIM, Orphanet, orphan drug designations, clinical trial activity, and published prevalence data.
Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
NA
Mayo Clinic
RECRUITING
426 publications have been identified in PubMed for inflammatory disease. Kisho has analyzed 251 by research type. Research spans Review / Meta-Analysis (41%), Epidemiology / Natural History (23%), and Basic Science / Preclinical (14%).
A recent study investigates the metabolic effects of GLP-1 receptor agonists in rheumatology patients, highlighting their potential impact on inflammatory outcomes. This single-center retrospective cohort analysis provides insights into the therapeutic implications for managing inflammation in these patients.
Isomorphic Labs, Apogee Therapeutics, and Avalo Therapeutics bagged the biggest biotech funding rounds overall in May 2026. The companies Isomorphic Labs, Apogee Therapeutics, and Avalo Therapeutics bagged the biggest biotech funding rounds overall in May 2026 across private and public funding types. Meanwhile, in second place, gene editing company Editas Medicine announced a public offering of up to $319.4 million, and, in third place, immunology company Odyssey Therapeutics raised $304 million from an initial public offering (IPO) and concurrent private placement. It’s also worth noting that Artiva Biotherapeutics wasn’t far behind in fourth place after pricing a $300 million underwritten offering. Last month, the subsector of immunological diseases came out on top, attracting two rounds and $604 million in total. Despite the therapeutic subsectors of immunological diseases and oncology achieving the most rounds, with three each, it was AI and inflammatory diseases – courtesy of Isomorphic’s and Apogee’s huge financings – that brought in the largest amounts of money, respectively. Now, let’s check out the public biotech fundraising rounds that occurred in May 2026, breaking them down by value and therapeutic subsector. In second place, inflammatory diseases brought in $375 million, and, in third place, cardiovascular diseases attracted $319.4 million. Below is a graph showing a month-to-month comparison of private and public biotech fundraising, looking at the total amount of money raised per month in 2026.
Gilead Sciences acquires Ouro Medicines for $2.1 billion, aiming to enhance its pipeline of T cell engagers targeting inflammatory diseases. This follows Gilead's recent $7.8 billion acquisition of Arcellx, indicating a strong focus on expanding its therapeutic offerings.
Invea Therapeutics has withdrawn its $35 million IPO plan due to unfavorable market conditions. The biotech, focused on developing oral small molecules for inflammatory diseases, had aimed to offer 3.2 million shares priced between $10 and $12.
Generate: Biomedicines successfully completed a $400 million IPO, marking the largest biotech IPO of the year. The funds will support clinical trials and R&D for their pipeline focused on cancer and inflammatory and immune diseases.
